HEXAL-LISINOPRIL™ 20 tablets

Country: South Africa

Language: English

Source: South African Health Products Regulatory Authority (SAHPRA)

Available from:

Hexal

Patient Information leaflet

INDICATIONS [/za_1232.html#1]
  [/za_1232.html#1]     [/za_1232.html#1]
CONTRA-INDICATIONS [/za_1232.html#1]
      [/za_1232.html#1]
DOSAGE [/za_1232.html#1]
      [/za_1232.html#1]
SIDE-EFFECTS [/za_1232.html#1]
  [/za_1232.html#1]     [/za_1232.html#1]
PREGNANCY [/za_1232.html#1]
      [/za_1232.html#1]
OVERDOSE [/za_1232.html#1]

IDENTIFICATION [/za_1232.html#1]
  [/za_1232.html#1]    PATIENT INFORMATION
HEXAL-LISINOPRIL™ 5 TABLETS
HEXAL-LISINOPRIL™ 10 TABLETS
HEXAL-LISINOPRIL™ 20 TABLETS
SCHEDULING STATUS:
S3
PROPRIETARY NAME
(and dosage form):
HEXAL-LISINOPRIL™ 5 TABLETS
HEXAL-LISINOPRIL™ 10 TABLETS
HEXAL-LISINOPRIL™ 20 TABLETS
COMPOSITION
Each HEXAL-LISINOPRIL 5 tablet contains 5 mg 
LISINOPRIL
 as the dihydrate.
Each HEXAL-LISNOPRIL 10 tablet contains 10 mg lisinopril as the dihydrate.
Each HEXAL-LISINOPRIL 20 tablet contains 20 mg lisinopril as the dihydrate. 
PHARMACOLOGICAL CLASSIFICATION
A.7.1.3 Other hypotensives
PHARMACOLOGICAL ACTION
Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme (ACE) that catalyses the
conversion of angiotensin I to the vasoconstrictor peptide angiotensin II. Angiotensin II also stimulates aldosterone
secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in
decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may result in an increase in
serum potassium concentration.
While the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the
renin-angiotensin-aldosterone system, lisinopril is also antihypertensive in patients with low-renin hypertension. ACE is
identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent
vasodilatory peptide, pl